Eli Lilly Designs P-Tau Biomarker Assay for Early Alzheimer’s Disease Diagnosis
The Pharma Data
NOVEMBER 10, 2020
Although a few are out there, phosphorylated tau (P-tau) may enable even earlier and more accurate detection, according to Eli Lilly-associated researchers speaking at the Clinical Trials on Alzheimer’s Disease (CTAD) virtual conference in early November. ADNI trial. The protocol was identical to the U.S.
52 
Let's personalize your content